<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078659</url>
  </required_header>
  <id_info>
    <org_study_id>MS ∕18.08.247</org_study_id>
    <nct_id>NCT04078659</nct_id>
  </id_info>
  <brief_title>Propofol and Magnesium Sulfate Intravenous Infusion During Endoscopic Sinus Surgery</brief_title>
  <official_title>Controlled Hypotension During Endoscopic Sinus Surgery: A Comparison of Propofol and Magnesium Sulfate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic Sinus surgery usually associated by bleeding, despite using of local vasopressor
      injection, head up position- controlled hypotension is generally used for control of this
      purpose.

      Propofol has been reported as a good agent for controlled hypotension by decreasing systemic
      vascular resistance secondary to arterial and venous vasodilation and a decrease in
      myocardial contractility with a dose-dependent property.

      Magnesium Sulfate also has been reported as an agent of hypotensive anaesthesia by inhibition
      of the release of norepinephrine by blocking N-type calcium channel at the nerve ending
      beside acting as a vasodilator.

      The well known pharmacodynamic effects of the intravenous infusion of propofol or Magnesium
      Sulfate may prove the advantage of this group in controlling intraoperative blood pressure
      thus reducing surgical field bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the work to compare the efficacy of propofol and magnesium sulfate to control
      blood pressure during endoscopic sinus surgery and the resultant effects on the quality of
      the surgical field including bleeding and visibility.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean arterial blood pressure (MAP)</measure>
    <time_frame>15 minutes after the induction of the hypotensive agent</time_frame>
    <description>automatically non invasive measured every 3 minutes , recorded every 15 minutes till the end and 15 minutes after extubation the end and 15 minutes after extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The blood loss</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>The blood loss would be calculated using the following formula Blood Loss = Blood Volume. In )Hct 1 / Hct2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients will need nitroglycerine and dose</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>The number of patients will need nitroglycerine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Ephedrine</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>The number of patients will need ephedrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>at the end of the surgery</time_frame>
    <description>The number of patient need for blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Ramsey sedation</measure>
    <time_frame>for the first hour postoperative</time_frame>
    <description>patient awake, anxious, agitated or restless 2 patient awake -1co operative, oriented and tranquil 3 patient drowsy with respond to command 4 patient asleep brisk response to glabella tap or loud auditory sound 5 patient asleep with sluggish response to stimulus 6 patient hasno response to nail bed pressure or othernoxious stimuli</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified post operative nausea and vomiting score</measure>
    <time_frame>for the first 24 hour postoperative</time_frame>
    <description>using impact scale score evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>one hour after extubation</time_frame>
    <description>time needed to reach modified aldrete score&gt; or=9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR)</measure>
    <time_frame>15 minutes after the start of the hypotensive agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical field assessment</measure>
    <time_frame>2 hours intraoperative</time_frame>
    <description>By the surgeon interms of bleeding and visibility using a 6-option Liker-scale scale adapted from Fromme el al. (26): 0 = no bleeding; 1 = minor bleeding, but no aspiration required; 2 = minor bleeding, aspiration required; 3 = minor bleeding, frequent aspiration required; 4 = moderate bleeding, visible� only with aspiration; 5 = severe bleeding, continuous aspiration required</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Endoscopic Sinus Surgery</condition>
  <arm_group>
    <arm_group_label>Propofol infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received intravenous Propofol infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received intravenous Magnesium Sulfate infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol infusion</intervention_name>
    <description>Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)</description>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate infusion</intervention_name>
    <description>Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Patients will receive propofol in a dose of 1-2 mg /kg</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atracurium</intervention_name>
    <description>Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanical Ventilation</intervention_name>
    <description>Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute</description>
    <arm_group_label>Magnesium Sulfate infusion</arm_group_label>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists Physical Classes I or II

        Exclusion Criteria:

          -  Patients refusal

          -  Patients with hypersensitivity for any drug used in the study including magnesium,
             propofol or isoflurane

          -  Patients receiving magnesium sulfate supplementation

          -  Patients receiving drugs known to have significant interaction.

          -  Patients with ischemic heart disease

          -  Patients with heart defects

          -  Patients with significant heart failure

          -  Patients with increased intracranial pressure.

          -  Patients with systemic hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazem E Moawed</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Anesthesia and Surgical Intensive Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nabil A Abd El-Mageed, MD</last_name>
    <phone>00201001538648</phone>
    <phone_ext>00201121516041</phone_ext>
    <email>nabil-abdelraouf@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hazem E Moawed, MD</last_name>
    <phone>00201121516041</phone>
    <phone_ext>00201121516041</phone_ext>
    <email>hazemmoawad@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nabil A Abd El-Mageed</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Nabil A Abd El-Mageed, MD</last_name>
      <phone>00201001538648</phone>
      <phone_ext>00201001538648</phone_ext>
      <email>nabil-abdelraouf@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Hazem E Meawad, MD</last_name>
      <phone>00201121516041</phone>
      <email>hazemmoawad@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maha A Abo-Zeid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed E Mohamed, M.Sec</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Atracurium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

